Drug manufacturers must make a strong showing to prove FDA preemption defeats plaintiffs’ failure to warn claims.
The Supreme Court reinforced the longstanding rule that even a non-public sale may invalidate a patent.
![Helsinn v Teva DRAFT[22600]](https://mk0caseymargoliikf5b.kinstacdn.com/wp-content/uploads/2019/01/HelsinnvTeva-1.jpg "Helsinn v Teva DRAFT[22600]")
